Feeds › Clinical trial updates
Clinical trial updates
Drug and device trials that companies register on ClinicalTrials.gov: newly completed phase 3 studies, changes of status and the dates a study is due to finish.
About this data
- What it is
- ClinicalTrials.gov is the US registry of clinical studies. Drug and device makers register their trials there and update the record as each study moves on. We list the studies that companies sponsor, and match the sponsor to a public company when the name lines up. The page opens on Phase 3 studies marked completed, the late-stage trials that come before a request for approval. Change View to see the changes of status we have noticed, or every recent update.
- Who files it
- The sponsor of the study, in its record on ClinicalTrials.gov. The registry is run by the US National Library of Medicine and does not check what sponsors report.
- How current
- We check the registry every day. Sponsors update records on their own schedule, from the same week to months later, so a change can appear in the registry well after it happened.
- Terms
- ClinicalTrials.govClinicalTrials.gov is the US government's registry of clinical studies, run by the National Library of Medicine. Sponsors register a study before it starts and update the record as it goes. The registry does not check what a sponsor reports.Phase 3The late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.statusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).completedThe sponsor has marked the study as finished. It says nothing about whether the treatment worked: results, if any, are reported separately and often later.status changesOur history of status changes starts the day we first stored each study, so a change made before that is not shown. The date is when we noticed the change, which can be later than when the sponsor made it.primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.company matchWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.
- Worth knowing
- A completed study is not a result: the registry says the study ended, not whether the treatment worked. Status changes start on the day we first stored each study, so earlier changes are not shown. Dates are the sponsor's own, and an estimated date can pass without an update. We match sponsors to companies automatically, with a hand-checked list for the large drugmakers, so a study with no ticker may still belong to a public company. This is information about studies, not a forecast of what they will show or of a stock's price.
- Not to be confused with
- FDA approvals and clearances: what the FDA decided, not what a sponsor reports about a study.
All of this comes from ClinicalTrials.gov, the US registry of clinical studies. We are not affiliated with it.
Source and freshness · Information, not investment advice (disclaimer).
Studies updated per day, last 30 days
All industry-sponsored studies Sponsor matched to a public company
By the day the sponsor last updated the study's record. A study updated twice counts once, on its latest day.
Latest clinical trial updates
Showing: ticker RYTM · All recent updates
Studies by the date their record was last updated.
| Updated | Study | SponsorWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private. | PhaseThe late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages. | StatusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time). | Enrolled | Primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update. | Source |
|---|---|---|---|---|---|---|---|
| Nov 13, 2026 | A Study of Setmelanotide in Patients With Prader-Willi Syndrome NCT06772597 · Prader-Willi Syndrome, Obesity Setmelanotide | RYTM Rhythm Pharmaceuticals, Inc. | Phase 2 | Active, not recruiting | 18 | Nov 3, 2026 | Registry ↗ |
| Nov 12, 2026 | EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway NCT05093634 · Obesity, Genetic Obesity Setmelanotide, Placebo | RYTM Rhythm Pharmaceuticals, Inc. | Phase 3 | Completed | 296 | Dec 19, 2025 | Registry ↗ |
| Oct 30, 2026 | A Study to Assess Efficacy and Safety of LB54640 in Patients With Hypothalamic Obesity NCT06046443 · Hypothalamic Obesity Bivamelagon, Placebo | RYTM Rhythm Pharmaceuticals, Inc. | Phase 2 | Completed | 28 | Feb 9, 2026 | Registry ↗ |
| Oct 9, 2026 | A Study of RM-718 in Healthy Subjects and Patients With MC4R Pathway Impairment NCT06239116 · Hypothalamic Obesity, Prader-Willi Syndrome Part A: RM-718 or placebo (matched to specific RM-718 dose… | RYTM Rhythm Pharmaceuticals, Inc. | Phase 1/2 | Active, not recruiting | 111 | May 7, 2027 | Registry ↗ |
| Aug 10, 2026 | A Trial of Setmelanotide in Acquired Hypothalamic Obesity NCT05774756 · Hypothalamic Obesity Setmelanotide, Placebo | RYTM Rhythm Pharmaceuticals, Inc. | Phase 3 | Active, not recruiting | 143 | Mar 18, 2025 | Registry ↗ |
| Jul 15, 2026 | Open-Label Extension Study of Setmelanotide NCT06596135 · Obesity Associated With Defects in Leptin-melanocortin Path… Setmelanotide | RYTM Rhythm Pharmaceuticals, Inc. | Phase 3 | Completed | 28 | Jun 24, 2026 | Registry ↗ |
| Feb 12, 2026 | A Trial of Setmelanotide in Patients With Congenital Hypothalamic Obesity (Sub-study of NCT05774756) NCT06760546 · Hypothalamic Obesity, Multiple Pituitary Hormone Deficiency… Setmelanotide, Placebo | RYTM Rhythm Pharmaceuticals, Inc. | Phase 3 | Recruiting | 39 | Mar 13, 2027 | Registry ↗ |
| Feb 10, 2026 | A Long-Term Study of Bivamelagon in Participants With Hypothalamic Obesity (HO) NCT07156578 · Hypothalamic Obesity Bivamelagon | RYTM Rhythm Pharmaceuticals, Inc. | Phase 2 | Enrolling by invitation | 25 | Apr 15, 2028 | Registry ↗ |
| Jul 2, 2025 | DAYBREAK: A Study of Setmelanotide in Participants With Specific Gene Variants in the Melanocortin-… NCT04963231 · Genetic Obesity Setmelanotide, Placebo | RYTM Rhythm Pharmaceuticals, Inc. | Phase 2 | Completed | 164 | Aug 4, 2023 | Registry ↗ |
| May 31, 2025 | Long Term Extension Trial of Setmelanotide NCT03651765 · Obesity Associated With Defects in Leptin-melanocortin Path… Setmelanotide | RYTM Rhythm Pharmaceuticals, Inc. | Phase 2/3 | Completed | 205 | Jan 9, 2025 | Registry ↗ |
| Feb 7, 2025 | Open-Label Study of Setmelanotide in Hypothalamic Obesity NCT04725240 · Hypothalamic Obesity Setmelanotide | RYTM Rhythm Pharmaceuticals, Inc. | Phase 2 | Completed | 18 | Jun 28, 2022 | Registry ↗ |
| Nov 27, 2024 | Setmelanotide in Pediatric Participants With Rare Genetic Diseases of Obesity NCT04966741 · Bardet-Biedl Syndrome, POMC Deficiency Obesity Setmelanotide | RYTM Rhythm Pharmaceuticals, Inc. | Phase 3 | Completed | 12 | Sep 18, 2023 | Registry ↗ |
| Nov 26, 2024 | Phase 3 Crossover Trial of Two Formulations of Setmelanotide in Participants With Specific Gene Def… NCT05194124 · Bardet-Biedl Syndrome, POMC Deficiency Setmelanotide 2 mg, Setmelanotide 2.5 mg | RYTM Rhythm Pharmaceuticals, Inc. | Phase 3 | Completed | 19 | Oct 19, 2023 | Registry ↗ |
| May 3, 2024 | Study of Setmelanotide Effects on QTc (Corrected QT) Interval in Healthy Participants NCT05046132 · Healthy Setmelanotide, Moxifloxacin | RYTM Rhythm Pharmaceuticals, Inc. | Phase 4 | Completed | 77 | Apr 7, 2022 | Registry ↗ |
| Dec 1, 2023 | Setmelanotide (RM-493), Melanocortin-4 Receptor (MC4R) Agonist, in Bardet-Biedl Syndrome (BBS) and… NCT03746522 · Bardet Biedl Syndrome (BBS), Alström Syndrome (AS) Setmelanotide, Placebo | RYTM Rhythm Pharmaceuticals, Inc. | Phase 3 | Completed | 52 | Nov 16, 2020 | Registry ↗ |
| Sep 21, 2023 | Setmelanotide for the Treatment of Early-Onset Pro-Opiomelanocortin (POMC) Deficiency Obesity NCT02896192 · Pro-opiomelanocortin (POMC) Deficiency Obesity Setmelanotide, Placebo | RYTM Rhythm Pharmaceuticals, Inc. | Phase 3 | Completed | 15 | May 25, 2020 | Registry ↗ |
| Aug 18, 2023 | Setmelanotide Phase 2 Treatment Trial in Participants With Rare Genetic Disorders of Obesity NCT03013543 · Genetic Obesity, Obesity Setmelanotide | RYTM Rhythm Pharmaceuticals, Inc. | Phase 2 | Completed | 213 | Mar 1, 2022 | Registry ↗ |
| Aug 14, 2023 | Phase 2 Study to Evaluate Safety and Efficacy of RM-493 in Obese Participants NCT01749137 · Overweight Setmelanotide, Placebo | RYTM Rhythm Pharmaceuticals, Inc. | Phase 2 | Completed | 74 | Sep 28, 2013 | Registry ↗ |
| Aug 7, 2023 | Phase 1b/2a Study to Evaluate Safety and Efficacy of Setmelanotide in Obese Patients NCT02041195 · Overweight and Obesity Setmelanotide, Placebo | RYTM Rhythm Pharmaceuticals, Inc. | Phase 1/2 | Completed | 99 | Aug 2014 | Registry ↗ |
| Jul 27, 2023 | Phase 2 Trial to Evaluate Safety and Efficacy of Setmelanotide (RM-493) in Obese Participants With… NCT02311673 · Prader-Willi Syndrome Setmelanotide, Placebo | RYTM Rhythm Pharmaceuticals, Inc. | Phase 2 | Completed | 40 | Oct 26, 2016 | Registry ↗ |
| May 23, 2023 | Setmelanotide for the Treatment of Leptin Receptor (LEPR) Deficiency Obesity NCT03287960 · Leptin Receptor Deficiency Obesity Setmelanotide, Placebo | RYTM Rhythm Pharmaceuticals, Inc. | Phase 3 | Completed | 15 | Sep 25, 2020 | Registry ↗ |
| Nov 15, 2022 | Genetic Testing and Phenotypic Characterization of Severely Obese Pediatric and Adult Volunteers NCT02849977 · Pro-opiomelanocortin (POMC), Proprotein Convertase Subtilis… | RYTM Rhythm Pharmaceuticals, Inc. | — | Completed | 5,966 | Jun 9, 2020 | Registry ↗ |
| Aug 10, 2022 | An Expanded Access Protocol for Setmelanotide for Treatment of Bardet-Biedl Syndrome (BBS) NCT05183802 · Bardet-Biedl Syndrome (BBS), Obesity Setmelanotide, administered subcutaneously [SC], once daily. | RYTM Rhythm Pharmaceuticals, Inc. | — | Approved for marketing | — | — | Registry ↗ |
| Jan 4, 2022 | Setmelanotide in a Single Patient With Partial Lipodystrophy NCT03262610 · Hypertriglyceridemia, Obesity Setmelanotide | RYTM Rhythm Pharmaceuticals, Inc. | Phase 2 | Completed | 1 | Jan 31, 2018 | Registry ↗ |
| Jun 30, 2021 | A Phase 1 Study to Evaluate the Pharmacokinetics of Setmelanotide in Subjects With Varying Degrees… NCT04348175 · Renal Insufficiency Setmelanotide | RYTM Rhythm Pharmaceuticals, Inc. | Phase 1 | Completed | 32 | Apr 17, 2021 | Registry ↗ |
| Jun 30, 2021 | An Observational,Prospective Natural History Study of Early-Onset Extreme Obesity Due to Bi-Allelic… NCT03621007 · POMC Deficiency Obesity, PCSK1 Deficiency Obesity | RYTM Rhythm Pharmaceuticals, Inc. | — | Completed | 8 | Jan 22, 2021 | Registry ↗ |
| May 4, 2021 | The TEMPO (Tracing the Effect of the MC4 Pathway in Obesity) Registry NCT03479437 · Genetic Forms of Extreme Obesity | RYTM Rhythm Pharmaceuticals, Inc. | — | Completed | 303 | Dec 1, 2020 | Registry ↗ |
| Apr 20, 2017 | Effects of RM-493 on Energy Expenditure in Obese Individuals NCT01867437 · Obesity, Morbid Obesity Placebo, RM-493 | RYTM Rhythm Pharmaceuticals, Inc. | Phase 1 | Completed | 15 | Mar 2014 | Registry ↗ |
| May 1, 2015 | Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RM-493 Administere… NCT02431442 · Overweight, Obese RM-493, Placebo | RYTM Rhythm Pharmaceuticals, Inc. | Phase 1 | Completed | 57 | Jan 2014 | Registry ↗ |
29 items, most recent first (up to 50). Each row links to the study's page on ClinicalTrials.gov. Updated Nov 15, 2026, 6:06 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · FDA approvals and clearances